checkAd

     131  0 Kommentare Microbix Announces Quality Products Distribution Agreement - Seite 2

    Andreas Simons, Director of Product Management, Clinical Diagnostics for R-Biopharm stated, “We’re pleased to secure access to Microbix’s innovative QAPs for sexually-transmitted, respiratory, and gastrointestinal infections as a complementary portfolio for our laboratory customers. There is an ever-increasing need to improve the accuracy of clinical diagnostic testing that these products will help address. Training of R-Biopharm staff about QAPs is already well advanced and we are now beginning to stock this product portfolio.

    About Microbix Biosystems
    Microbix develops proprietary biological and technology solutions for human health and well-being, with approximately 80 skilled employees and sales now exceeding $1 million per month on average. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure quality control of clinical diagnostic tests. Microbix antigens and QAPs are sold to many customers worldwide, at present primarily to multinational diagnostics companies and laboratory accreditation organizations. Microbix is ISO 9001 and 13485 accredited, FDA and Health Canada establishment licensed, and provides CE marked products.

    Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic urokinase, a biologic thrombolytic drug used to treat blood clots.

    Microbix is a publicly-traded company, listed on the Toronto Stock Exchange and headquartered in Mississauga, Ontario, Canada. Distribution inquiries should be directed to sarah.sokol@microbix.com.

    About R-Biopharm AG
    R-Biopharm AG, a privately-owned company based in Darmstadt, Germany, is a globally active biotechnology company and a leading provider of reliable test systems for clinical diagnostics, companion diagnostics, and for analyzing human food and animal feedstuffs. Since 1988, R-Biopharm has been developing innovative products characterized by top quality, reliability and efficiency. A strong sense of responsibility, long-standing experience and a network of more than twenty affiliated companies and subsidiaries in Europe, the U.S., Canada, Brazil, Latin America, China, India and Australia, as well as more than 120 distribution partners, make R-Biopharm a prime partner for clients from retail, industry and public institutions looking for answers and solutions for current and future analytical challenges. Please visit www.r-biopharm.com for more information.

    Seite 2 von 3




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Microbix Announces Quality Products Distribution Agreement - Seite 2 Appointment of R-Biopharm AG for 11 CountriesMISSISSAUGA, Ontario, May 15, 2020 (GLOBE NEWSWIRE) - Microbix Biosystems Inc. (TSX: MBX, Microbix), an award-winning life sciences innovator and exporter, announces the appointment of R-Biopharm AG …